InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: None

Thursday, 01/26/2017 7:55:39 AM

Thursday, January 26, 2017 7:55:39 AM

Post# of 807
CTL019 on its pipeline of possible blockbusters, underscoring its confidence in the product’s commercial potential. Despite logistical challenges, we forecast at least $1bn WW peak sales for £65-75m income to OXB (Oxford BioMedica) p.a. providing an important sustainable revenue stream for c.5p/share NPV at 80% probability, more than underpinning the current share price.”

HTTPS://endpts.com/fighting-a-generic-onslaught-novartis-adds-car-t-to-its-growing-list-of-late-stage-blockbusters/


From pages 20,21 I make that 45,800 potential patients for CTL019

HTTPS://www.novartis.com/sites/www.novartis.com/files/q4-2016-ir-presentation-development.pdf